SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, commends the expansion of CGM Medicare coverage to ...
It was good news for Dexcom in January when the Centers for Medicare and Medicaid Services announced they would reimburse for Dexcom’s — and initially only Dexcom’s — continuous glucose monitor. Now ...
Medicare Part B typically covers continuous glucose monitors (CGMs) like the Dexcom G7, as they are Food and Drug Administration (FDA)-approved durable medical equipment items. To get a Dexcom G7 CGM ...
Dexcom Executive Vice President and Chief Commercial Officer RIck Doubleday visited The American Journal of Managed Care® to discuss Medicare reimbursement for the Dexcom G5 and a new partnership with ...
DexCom (NASDAQ:DXCM) added ~7% on Thursday after the Centers for Medicare and Medicaid Services (CMS) updated its policy on continuous glucose monitors to expand coverage for a broader group of ...
Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...
CMS opened up Medicare coverage for therapeutic continuous glucose monitors, eliminating a rule that beneficiaries must use a blood glucose monitor and require at least four self-monitoring blood ...
SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today the U.S. Centers for Medicare & Medicaid Services (CMS) is ...
A Dexcom spokeswoman said there are already 20,000 Medicare patients in the pipeline with almost no advertisement of the policy change. After hitting a few snags and finding a partner to create the ...
The Centers for Medicare and Medicaid Services has released guidelines on Medicare coverage for continuous glucose monitors, and one medtech company stands to make a whole lot of money from the change ...
Abbott announced Thursday that its continuous glucose monitoring system, requiring no routing fingerstick calibration for type 1 diabetes patients, will now be available to eligible Medicare patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback